Laurus Labs Limited (NSE:LAURUSLABS)
India · Delayed Price · Currency is INR | Market Cap | 635.74B +88.6% |
| Revenue (ttm) | 68.68B +23.7% |
| Net Income | 8.89B +148.0% |
| EPS | 16.45 +147.7% |
| Shares Out | 539.86M |
| PE Ratio | 71.59 |
| Forward PE | 57.81 |
| Dividend | 1.60 (0.14%) |
| Ex-Dividend Date | May 8, 2026 |
| Volume | 2,522,372 |
| Average Volume | 2,083,536 |
| Open | 1,188.70 |
| Previous Close | 1,177.60 |
| Day's Range | 1,183.70 - 1,223.70 |
| 52-Week Range | 572.25 - 1,223.70 |
| Beta | 0.35 |
| RSI | 69.69 |
| Earnings Date | Apr 30, 2026 |
About Laurus Labs
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition,... [Read more]
Financial Performance
In fiscal year 2026, Laurus Labs's revenue was 68.68 billion, an increase of 23.66% compared to the previous year's 55.54 billion. Earnings were 8.89 billion, an increase of 148.04%.
Financial StatementsNews
Laurus Labs Ltd (BOM:540222) Q4 2026 Earnings Call Highlights: Robust Revenue Growth and ...
Laurus Labs Ltd (BOM:540222) Q4 2026 Earnings Call Highlights: Robust Revenue Growth and Strategic Investments Propel Future Prospects
Q4 2026 Laurus Labs Ltd Earnings Call Transcript
Q4 2026 Laurus Labs Ltd Earnings Call Transcript
Laurus Labs Transcript: Q4 25/26
FY 2026 saw 23% revenue growth, margin expansion, and robust performance across CDMO and generics, with strong order books and major CapEx underway to support future growth. Gross margin and EBITDA margin reached record highs, and leverage improved.
Laurus Labs announces voluntary closure of Laurus Generics GmbH
Laurus Labs has announced the voluntary closure of its step-down wholly owned subsidiary, Laurus Generics GmbH, based in Germany. The decision was approved by the Board of Directors during their…
Laurus Labs approves €9.8 million investment in KRKA Pharma joint venture
Laurus Labs has announced a significant investment in its joint venture, KRKA Pharma Private Limited, amounting to up to €9.8 million. This strategic move, approved by the Board of Directors…
Laurus Labs reports ₹6,813 crore revenue for FY26 with 23% growth
Laurus Labs has announced its financial results for the fiscal year ending March 31, 2026, reporting a revenue of ₹6,813 crore, marking a 23% increase over the previous year. The…
Laurus Labs Q4 Results: Profit rises 19% YoY as margin expands nearly 400 bps
Laurus Labs Limited reported a strong growth in profitability for the quarter ended March 31, 2026, supported by steady revenue expansion and improved operating performance. The company’s revenue from...
Laurus Labs to invest ₹82 crore in joint venture and appoints two new independent directors
Laurus Labs Limited has announced significant strategic developments, including a substantial investment in its joint venture and the appointment of two new independent directors. The company's board ...
Laurus Labs receives creditor approval for composite scheme of arrangement
Laurus Labs has announced that the meetings of unsecured creditors for its subsidiaries, Laurus Synthesis and Sriam Labs, have successfully concluded with approval for the Composite Scheme of Arrangem...
Pharma sector stocks today, March 24: Shilpa Medicare jumps 3.28%, Glenmark Pharma up 1.36%, Laurus Labs gain 1.65%
The Indian pharmaceutical sector showed mixed movements in early trading, as of approximately 9:51 AM IST on March 24, 2026. The S&P BSE Healthcare Index stood at 41,630.4, reflecting a…
Pharma sector stocks surge today, March 20: Laurus Labs jumps 2.83%, Natco Pharma up 2.67%, Aurobindo Pharma gains 2.42%
The pharmaceutical sector in India showed positive movement on March 20, 2026, during early trading hours. The S&P BSE HEALTHCARE Index stood at 42,149.5, reflecting a gain of 1.1%. This…
Pharma sector stocks fall today, March 19: Biocon down 2.33%, Laurus Labs falls 2.29%, Glenmark Pharma drops 2%
Pharmaceutical stocks in India experienced a decline on March 19, 2026, during early trading hours. Market data as of approximately 9:46 AM IST (BSE) and 9:49 AM IST (NSE) showed…
Pharma sector stocks today, March 13: Laurus Labs down 2.56%, Ajanta Pharma falls 1.88%, Granules India drops 2.14%
The Indian pharmaceutical sector showed a downward trend in early trading on March 13, 2026, aligning with broader market weakness. The S&P BSE Healthcare Index stood at 43,441.0, down 0.6%…
Pharma sector fall sharply otday, March 9: Laurus Labs down 3%, Glenmark Pharma drops 2.44%, Zydus Life falls 2.10%
The Indian pharmaceutical sector experienced declines on March 9, 2026, amid broader market weakness. As of approximately 9:36-9:39 AM IST, most listed pharma stocks traded lower on both BSE and…
Laurus Labs Ltd (BOM:540222) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and ...
Laurus Labs Ltd (BOM:540222) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments Propel Performance
Q3 2026 Laurus Labs Ltd Earnings Call Transcript
Q3 2026 Laurus Labs Ltd Earnings Call Transcript
Laurus Labs Transcript: Q3 25/26
Q3 FY2026 saw robust revenue and margin growth, led by generics and CDMO, with strong ARV performance and continued investments in advanced manufacturing and R&D. Gross margins are expected to remain stable, and CapEx will exceed INR 1,000 crores annually.
Laurus Labs betting big on CDMO segment to power future growth
Hyderabad: Pharma player Laurus Labs is betting big on the rapidly growing contract development and manufacturing organisation (CDMO) segment as a key.
GAIL, Swiggy & more: Top stocks to buy on December 2 — check list
Brokerages offer mixed views on Indian stocks. HSBC is bullish on GAIL, Jefferies on Kfin Tech, and Kotak on Swiggy. Citigroup, however, rates Laurus Laboratories a sell. Goldman Sachs maintains a neu...
Laurus Labs shares rise over 2% today as US FDA concludes “no quality unit oversight” at Hetero Labs’ Vishakhapatnam warehouse
Mumbai, October 27 (Monday): Shares of Laurus Labs Ltd gained 2.37% to ₹948.35 in early trading, extending their upward momentum...
Top stocks to buy: Stock recommendations for the week starting October 27, 2025 - check list
Stock market recommendations:Motilal Oswal Financial Services has identified Laurus Labs and 360 ONE WAM as top stock picks for Diwali week. Laurus Labs' strong quarterly performance and expansion pla...
Top stocks to buy today: Stock recommendations for October 27, 2025 - check list
Macquarie maintains an outperform rating on Hindustan Unilever, anticipating sales growth above 4% driven by demand recovery and GST transition reversal. CLSA holds Colgate Palmolive with a target pri...
DAM Capital bullish on Laurus Labs, cites CDMO traction and lower net debt in strong Q2
DAM Capital has reiterated its buy rating on Laurus Labs with a target price of ₹1,083 per share after a...
Goldman Sachs cautious on Laurus despite 126% YoY EBITDA growth; valuations seen full
Goldman Sachs has maintained its sell rating on Laurus Labs with a target price of ₹775 per share following a...
Jefferies cautious on Laurus Labs despite Q2 beat; $600m Vizag capex to extend investment cycle
Jefferies has maintained its underperform rating on Laurus Labs while raising its target price to ₹700 per share following the...